Early Magnesium Sulfate Linked to Lower Mortality in Pneumonia

Magnesium Homeostasis in Severe Respiratory Infection

Pneumonia remains a primary driver of critical illness, contributing significantly to global mortality and placing a heavy burden on intensive care resources [1]. While standard management protocols emphasize prompt antimicrobial therapy and supportive respiratory care, the role of adjunctive electrolyte interventions in modulating the course of severe infection is increasingly scrutinized [2, 3]. Magnesium sulfate is already a staple in the clinical armamentarium, utilized for everything from managing neuromuscular excitability in tetanus to serving as an adjunct in postoperative pain management [4, 5]. Despite its widespread use, the specific impact of magnesium on systemic outcomes in acute respiratory infections has historically lacked robust evidence, often leaving clinicians to focus solely on correcting overt deficiency [6]. To address this knowledge gap, researchers conducted a retrospective analysis to determine whether the early administration of intravenous magnesium sulfate correlates with improved survival in critically ill patients hospitalized with pneumonia.

Retrospective Analysis of ICU Outcomes

To investigate the potential survival benefits of magnesium, researchers conducted a retrospective observational cohort study using the Medical Information Mart for Intensive Care IV (MIMIC-IV) version 3.1 database. This extensive clinical repository provided a comprehensive dataset for 9,203 eligible critically ill patients admitted to the intensive care unit (ICU) with pneumonia. By utilizing this data, the authors aimed to determine if the timing of magnesium administration influenced all-cause mortality across 30-day, 60-day, and 90-day intervals. The study specifically focused on the impact of early intervention during the acute resuscitation phase, defining early exposure as the administration of intravenous magnesium sulfate within a narrow clinical window: from 6 hours before to 24 hours after ICU admission. Within this cohort, 2,975 individuals (32.3%) received early intravenous magnesium sulfate, while the remainder served as the non-exposure group. This distribution allowed for a robust comparison of outcomes using propensity score matching (a statistical technique that balances baseline patient characteristics to mimic the conditions of a randomized trial) to control for confounding variables such as baseline illness severity and comorbidities.

Survival Benefits Across Short and Long Term

The researchers designated 30-day all-cause mortality as the primary outcome to assess the immediate impact of early intervention on patient survival. To account for potential confounders and determine the independent effect of the treatment, associations were evaluated using multivariable Cox proportional hazards models (a statistical method that estimates the risk of an event occurring over time while adjusting for multiple independent variables). The analysis demonstrated that early magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment, yielding an adjusted hazard ratio (aHR) of 0.84 (95% confidence interval [CI] 0.76-0.94; p = .002). This finding indicates a 16% reduction in the risk of death within the first month of ICU admission for patients receiving the supplement, suggesting that a simple, inexpensive electrolyte intervention could meaningfully alter the trajectory of severe respiratory infections. The survival benefit observed in the initial month appeared to persist throughout the extended follow-up periods, indicating that the impact of early magnesium stabilization is not merely transient. Secondary outcomes included 60-day and 90-day mortality, both of which showed consistent associations with early magnesium exposure. Specifically, early magnesium sulfate administration was associated with lower 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and lower 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). These data points suggest that the physiological advantages conferred by magnesium during the acute phase of pneumonia may have lasting implications for patient recovery and long-term prognosis.

Statistical Rigor and Sepsis Interactions

To validate the primary findings and account for potential selection bias inherent in retrospective data, the researchers conducted several prespecified analyses, including subgroup, interaction, and sensitivity evaluations. A critical component of this validation involved propensity score matching to ensure the treatment and control groups were directly comparable. In the propensity score-matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality, yielding an adjusted hazard ratio (aHR) of 0.85 (95% confidence interval [CI] 0.74-0.96; p = .012). This consistency across different statistical models reinforces the association between early magnesium exposure and improved survival outcomes in the intensive care setting. The study further examined how specific clinical phenotypes might influence the efficacy of the intervention. A subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007), indicating that the presence of systemic infection may be a key determinant in how patients respond to magnesium supplementation. For practicing physicians, this suggests that patients with pneumonia who progress to sepsis might represent a specific subgroup where magnesium homeostasis is particularly critical. Ultimately, the researchers concluded that early intravenous magnesium sulfate administration was associated with lower mortality in critically ill patients with pneumonia. However, they noted that these findings are hypothesis-generating and do not yet establish a definitive standard of care. The authors emphasize the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation to maximize clinical benefit in this vulnerable population.

References

1. Roberton T, Carter ED, Chou VB, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. The Lancet Global Health. 2020. doi:10.1016/s2214-109x(20)30229-1

2. Sweet DG, Carnielli V, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. Neonatology. 2019. doi:10.1159/000499361

3. Manti S, Staiano A, Orfeo L, et al. UPDATE - 2022 Italian guidelines on the management of bronchiolitis in infants. ˜The œItalian Journal of Pediatrics/Italian journal of pediatrics. 2023. doi:10.1186/s13052-022-01392-6

4. Aldamluji N, Burgess AE, Pogatzki‐Zahn E, Ræder J, Beloeil H, collaborators TPWG. PROSPECT guideline for tonsillectomy: systematic review and procedure‐specific postoperative pain management recommendations. Anaesthesia*. 2020. doi:10.1111/anae.15299

5. Edward Y, Santoso KH. Uncommon intraoral source of generalized tetanus: Case report and review of intensive care strategies.. IDCases. 2026. doi:10.1016/j.idcr.2026.e02530

6. Ujano SA, Manalo GL. Magnesium Sulfate Use in Adult Patients with Tetanus at Mariano Marcos Memorial Hospital & Medical Center. Philippine journal of internal medicine. 2025. doi:10.65564/pjim.1293e96cef